Linked Life Data

12745649

Source:http://linkedlifedata.com/resource/pubmed/id/12745649

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-5-14
pubmed:abstractText
Chronic myeloid leukemia (CML) is a hematological neoplasia that results from the transformation of a hematopoietic stem cell. It is characterized by the expansion of the myeloid lineage, which results in the accumulation of mature and immature granulocytes in peripheral blood and bone marrow. However, when CML marrow cells are cultured in Dexter-type long-term cultures (LTMC) hematopoiesis is defective and can be sustained for only a few weeks. One possible explanation for the deficient growth of hematopoietic cells in CML LTMC is that some factors that act as key regulators of hematopoiesis are absent in this experimental system. Thus, we tested this hypothesis by adding recombinant cytokines to these cultures. As a first approach, we added recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), rhGranulocyte-CSF (rhG-CSF) and rhErythropoietin (rhEPO); each factor was added individually once a week. Addition of rhGM-CSF and rhG-CSF resulted in a significant increase in the levels of nucleated cells and myeloid progenitors; the highest effects were seen in the presence of rhGM-CSF. Interestingly, such a cytokine also induced a significant decrease in the levels of erythroid progenitors. Recombinant hEPO had no significant effects on nucleated cells or myeloid progenitors, however, it induced a significant, although transient, increase in the levels of erythroid cells. The above results indicate that the hematopoietic regulators used here (rhGM-CSF, rhG-CSF and rhEPO) are capable of stimulating the growth of hematopoietic cells in LTMC from CML patients. Thus, this study demonstrates that it is, indeed, possible to manipulate CML LTMC by the addition of recombinant cytokines; this observation may be of particular relevance, since this in vitro experimental system has already been used as a method for purging of leukemic cells in autologous transplant settings. By using specific recombinant hematopoietic modulators it might be possible to make LTMC a more efficient system for such a clinical purpose.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1024-5332
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
155-63
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12745649-Adult, pubmed-meshheading:12745649-Aged, pubmed-meshheading:12745649-Aged, 80 and over, pubmed-meshheading:12745649-Bone Marrow Purging, pubmed-meshheading:12745649-Cell Lineage, pubmed-meshheading:12745649-Erythropoietin, pubmed-meshheading:12745649-Female, pubmed-meshheading:12745649-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:12745649-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:12745649-Hematopoiesis, pubmed-meshheading:12745649-Hematopoietic Stem Cells, pubmed-meshheading:12745649-Humans, pubmed-meshheading:12745649-Kinetics, pubmed-meshheading:12745649-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:12745649-Male, pubmed-meshheading:12745649-Middle Aged, pubmed-meshheading:12745649-Neoplastic Stem Cells, pubmed-meshheading:12745649-Recombinant Proteins, pubmed-meshheading:12745649-Tumor Cells, Cultured, pubmed-meshheading:12745649-Tumor Stem Cell Assay
pubmed:year
2003
pubmed:articleTitle
Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: effect of recombinant cytokines in dexter-type long-term cultures.
pubmed:affiliation
Oncological Research Unit, Oncology Hospital, Nationa Medical Center, IMSS, Mexico City, Mexico.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't